For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Gossamer Bio Inc (NASDAQ: GOSS) was $0.88 for the day, down -8.55% from the previous closing price of $0.96. In other words, the price has decreased by $-8.55 from its previous closing price. On the day, 1.41 million shares were traded. GOSS stock price reached its highest trading level at $0.9711 during the session, while it also had its lowest trading level at $0.8722.
Ratios:
Our analysis of GOSS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.88 and its Current Ratio is at 6.88. In the meantime, Its Debt-to-Equity ratio is 6.88 whereas as Long-Term Debt/Eq ratio is at 6.85.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on June 25, 2024, initiated with a Outperform rating and assigned the stock a target price of $9.
UBS Downgraded its Buy to Neutral on July 27, 2023, whereas the target price for the stock was revised from $8 to $1.25.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 24 ’24 when Aranda Richard sold 1,908 shares for $0.66 per share. The transaction valued at 1,260 led to the insider holds 196,891 shares of the business.
Hasnain Faheem bought 372,000 shares of GOSS for $250,282 on Jun 21 ’24. The President & CEO now owns 5,408,073 shares after completing the transaction at $0.67 per share. On Jun 18 ’24, another insider, Giraudo Bryan, who serves as the COO/CFO of the company, bought 100,000 shares for $0.59 each. As a result, the insider paid 59,110 and bolstered with 480,010 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GOSS now has a Market Capitalization of 222495168 and an Enterprise Value of 107500712. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.74 while its Price-to-Book (P/B) ratio in mrq is 6.73. Its current Enterprise Value per Revenue stands at 0.937 whereas that against EBITDA is -1.819.
Stock Price History:
The Beta on a monthly basis for GOSS is 1.83, which has changed by 0.2338028 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, GOSS has reached a high of $1.55, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -22.10%, while the 200-Day Moving Average is calculated to be -9.97%.
Shares Statistics:
GOSS traded an average of 1.61M shares per day over the past three months and 1513550 shares per day over the past ten days. A total of 226.60M shares are outstanding, with a floating share count of 182.60M. Insiders hold about 19.64% of the company’s shares, while institutions hold 58.90% stake in the company. Shares short for GOSS as of 1744675200 were 9172699 with a Short Ratio of 5.68, compared to 1741910400 on 5741046. Therefore, it implies a Short% of Shares Outstanding of 9172699 and a Short% of Float of 4.16.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Gossamer Bio Inc (GOSS) is presently subject to a detailed evaluation by 6.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $-0.19, with high estimates of $-0.17 and low estimates of $-0.23.
Analysts are recommending an EPS of between $-0.65 and $-0.94 for the fiscal current year, implying an average EPS of $-0.73. EPS for the following year is $-0.44, with 7.0 analysts recommending between $-0.12 and $-0.81.
Revenue Estimates
Based on 9 analysts’ estimates, the company’s revenue will be $54.87M in the next fiscal year. The high estimate is $120.4M and the low estimate is $16.67M.
